Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to tidy the Pharmalot grounds, promenade with our official mascot, and catch up on our reading. A few naps are on the schedule, too. And what about you? Summer is here, so perhaps this is an opportunity to visit a beach or lake. You could also plan a getaway, since it is now possible to get away (assuming you have been vaccinated, of course). Or simply plan the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon…

An expert panel voted to advise the Centers for Disease Control and Prevention that it recommend the use of a controversial dengue vaccine despite the fact that it can be given to only a small fraction of U.S. children and requires a pre-vaccination test to be used safely, STAT reports. The 14-0 vote by the Advisory Committee on Immunization Practices clears the way for Sanofi (SNY) to roll out its three-dose Dengvaxia vaccine, assuming the CDC accepts the advice. The CDC very rarely overrides recommendations from the group, known as ACIP.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment